CoChat

Evaluation of the Novel CE-IVD-Marked Multiplex PCR QIAstat-Dx Meningitis/Encephalitis Panel

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 13 of the 21 sources its claims cite were checked for support.

Abstract

The diagnosis of infectious meningitis and encephalitis relies mostly on specific PCR and culturing methods, but commercial syndromic panel assays are bringing a change in diagnostics. With multiplexed analysis, the identification of the pathogen is potentially faster, and less sample material is needed. The novel QIAstat-Dx meningitis/encephalitis panel assay is intended for the rapid identification of pathogens from cerebrospinal fluid for suspected central nervous system (CNS) infection, which is a life-threatening condition and difficult to diagnose. We studied the performance of this panel assay using patient samples and dilution series of selected viruses. The evaluation data for this novel meningitis/encephalitis panel assay are useful for other clinical laboratories and organizations using or considering using this test.

Overview

CoChat Summary

TL;DR

This retrospective single-center study evaluated the QIAstat-Dx meningitis/encephalitis (QIA/ME) multiplex PCR panel against the BioFire FilmArray ME panel and reference methods using frozen residual CSF samples, plus HSV-1/HSV-2/VZV dilution series. QIA/ME and FA/ME were broadly similar on patient samples, but QIA/ME showed some false negatives and poorer performance than FA/ME for herpesvirus dilution series.

Key findings

  • In patient samples, QIA/ME had positive percent agreement/negative percent agreement of 100% for all included pathogens except *S. pneumoniae*; for *S. pneumoniae*, NPA was 98.7% because one sample was positive by the diagnostic reference method and QIA/ME but negative by FA/ME.
  • Compared with the diagnostic reference methods, the overall PPA was 95.1% for QIA/ME and 93.8% for FA/ME.
  • For herpesvirus dilution series, real-time PCR methods with separate extraction were the most sensitive, and FA/ME performed better than QIA/ME overall.
  • QIA/ME had 3 errors and 4 failed results in 108 runs for a 6.5% total error rate; FA/ME had 0% error rate in 115 runs.
  • External quality control samples from QCMD showed 100% consistency with the expected results for both QIA/ME and FA/ME.

Methods

  • Retrospective single-center evaluation using frozen residual CSF samples sent to Helsinki University Hospital Laboratory from 2017 to 2022; 63 positive CSF samples (by reference method) and 16 clinical samples negative by FA/ME were included.
  • QIA/ME was run in parallel with FA/ME; results were compared with reference PCR methods or cultivation, and agreements were calculated as PPA and NPA using the study’s defined formulas.
  • A separate analytical comparison used HSV-1, HSV-2, and VZV dilution series (1:102 to 1:107) tested across six PCR methods, and QCMD 2021 CNS I external quality assessment samples were also tested.

Limitations

  • The paper states this was a retrospective single-center study using frozen residual CSF samples, and that samples were preselected based on availability; it says this does not represent real-life laboratory practice where most CSF samples are negative.
  • The study had a small sample size, with some bacterial targets absent entirely and others represented by only a few samples; it also had a narrow Cq range and lacked more challenging low-viral-load samples.
  • Evident from the text: several comparisons are based on very small numbers for specific pathogens (for example, only two HHV-6-positive samples), which limits precision of those pathogen-specific estimates.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1128/spectrum.05144-22

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

4 Valid · 0 Not valid · 4 Not checked · 56 Own results and interpretations

22 more claims

Create a free account to see all 64 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 32

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 21

Metadata

Authors
Humisto, A., Antikainen, J., Holma, T., Jarva, H., Toivonen, A., Loginov, R., & Mannonen, L.
Affiliations
University of Helsinki (FI)
Corresponding author
Humisto, Anu
Venue
Microbiology Spectrum
Published
2023-06-15
Volume
11
Issue
3
Pages
e0514422-e0514422
ISSN
2165-0497 (ISSN-L)
OpenAlex
W4365136212
Cited by
21
References
32
Citations by year
2026: 6 · 2025: 6 · 2024: 9
FWCI
4.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Microbiology Spectrum (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Työväentutkimus Vuosikirja (submittedVersion)
Funders
University of Helsinki Hospital laboratory, internal funding
Topics
  • Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
  • Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
multiplex PCR, meningitis, encephalitis, cerebrospinal fluid, central nervous system infection, virus detection, assay evaluation
MeSH terms
Bacteria, Encephalitis, Humans, Meningitis, Viruses, Multiplex Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of the Novel CE-IVD-Marked Multiplex PCR QIAstat-Dx Meningitis/Encephalitis Panel. https://app.cochat.ai/papers/10.1128/spectrum.05144-22
The paper
Humisto, A., Antikainen, J., Holma, T., Jarva, H., Toivonen, A., Loginov, R., & Mannonen, L. (2023). Evaluation of the Novel CE-IVD-Marked Multiplex PCR QIAstat-Dx Meningitis/Encephalitis Panel. Microbiology Spectrum. https://doi.org/10.1128/spectrum.05144-22

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.